ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| Weiss Ratings | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.07 | |||
| Price History | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.69% | |||
| 30-Day Total Return | -34.70% | |||
| 60-Day Total Return | 3.08% | |||
| 90-Day Total Return | -31.86% | |||
| Year to Date Total Return | -12.93% | |||
| 1-Year Total Return | -78.71% | |||
| 2-Year Total Return | -90.19% | |||
| 3-Year Total Return | -90.63% | |||
| 5-Year Total Return | -84.59% | |||
| 52-Week High % Change | -83.54% | |||
| 52-Week Low % Change | 48.15% | |||
| Price | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.43 | |||
| 52-Week Low Price | $0.27 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 07, 2024 | |||
| Valuation | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.41M | |||
| Enterprise Value | 22.66M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.76 | |||
| Earnings Per Share Growth | 63.24% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.64 | |||
| Price/Book (Q) | 0.52 | |||
| Enterprise Value/Revenue (TTM) | 1.28 | |||
| Price | $0.39 | |||
| Enterprise Value/EBITDA (TTM) | -2.90 | |||
| Enterprise Value/EBIT | -2.16 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 28.13M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 250 483 0308 | |||
| Address | 3204–4464 Markham Street Victoria, BC V8Z 7X8 | |||
| Website | www.ipatherapeutics.com | |||
| Country | Canada | |||
| Year Founded | 1983 | |||
| Profitability | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -59.23% | |||
| Profit Margin | -114.51% | |||
| Management Effectiveness | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -13.44% | |||
| Return on Equity | -- | |||
| Income Statement | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 17.70M | |||
| Total Revenue (TTM) | 17.70M | |||
| Revenue Per Share | $0.63 | |||
| Gross Profit (TTM) | 8.90M | |||
| EBITDA (TTM) | -7.82M | |||
| EBIT (TTM) | -10.48M | |||
| Net Income (TTM) | -20.27M | |||
| Net Income Avl. to Common (TTM) | -20.27M | |||
| Total Revenue Growth (Q YOY) | -0.95% | |||
| Earnings Growth (Q YOY) | -5.40% | |||
| EPS Diluted (TTM) | -0.76 | |||
| EPS Diluted Growth (Q YOY) | 6.07% | |||
| Balance Sheet | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.54M | |||
| Cash Per Share (Q) | $0.09 | |||
| Total Current Assets (Q) | 8.97M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 23.45M | |||
| Current Ratio (Q) | 1.008 | |||
| Book Value Per Share (Q) | $0.77 | |||
| Total Assets (Q) | 43.03M | |||
| Total Current Liabilities (Q) | 8.90M | |||
| Total Debt (Q) | 11.79M | |||
| Total Liabilities (Q) | 19.58M | |||
| Total Common Equity (Q) | 23.45M | |||
| Cash Flow | IPA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.02M | |||
| Cash from Financing (TTM) | 4.77M | |||
| Net Change in Cash (TTM) | -1.83M | |||
| Levered Free Cash Flow (TTM) | -1.37M | |||
| Cash from Operations (TTM) | -5.42M | |||
